NCT03590574 2026-03-16
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
Phase 1/2 Terminated
Clinical Trials
519 trialsNCT06173505 2026-03-13
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Phase 1/2 Terminated
NCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated
NCT05721222 2026-03-04
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Genmab
Phase 1/2 Terminated
NCT06171789 2026-02-25
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT06716853 2026-02-09
TEM-GU
Genenta Science
Phase 1/2 Terminated
NCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
NCT04913220 2026-02-04
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Sanofi
Phase 1/2 Terminated
NCT05756907 2026-02-03
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
Phase 1/2 Terminated
NCT04187404 2026-01-30
Spencer
Enterome
Phase 1/2 Terminated
NCT03215030 2026-01-29
iinnovate-1
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT04157517 2026-01-29
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05262530 2026-01-21
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
Phase 1/2 Terminated
NCT05357027 2026-01-21
HPV16 E6 TCR T Cells for Cervical Carcinoma
TCRCure Biopharma Ltd.
Phase 1/2 Terminated
NCT04799054 2026-01-20
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT05450562 2026-01-14
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT04643405 2026-01-08
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT04240002 2026-01-05
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Phase 1/2 Terminated
NCT04425070 2026-01-05
TOUCH
Antengene Corporation
Phase 1/2 Terminated
NCT06106841 2025-12-30
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Terminated
NCT06198426 2025-12-30
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Terminated
NCT03055286 2025-12-26
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
JW Pharmaceutical
Phase 1/2 Terminated
NCT06391775 2025-12-26
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab
Phase 1/2 Terminated
NCT04824794 2025-12-22
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated
NCT05086315 2025-12-15
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi
Phase 1/2 Terminated
NCT04844073 2025-12-04
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Takeda
Phase 1/2 Terminated
NCT03284957 2025-11-24
AMEERA-1
Sanofi
Phase 1/2 Terminated
NCT04725331 2025-11-21
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
Phase 1/2 Terminated
NCT05525286 2025-11-17
CLAUDIO-01
Sotio Biotech Inc.
Phase 1/2 Terminated
NCT03519178 2025-11-14
A Study of PF-06873600 in People With Cancer
Pfizer
Phase 1/2 Terminated
NCT05119335 2025-11-12
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
Phase 1/2 Terminated
NCT05194735 2025-11-10
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Phase 1/2 Terminated
NCT05617040 2025-11-10
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Barinthus Biotherapeutics
Phase 1/2 Terminated
NCT03837509 2025-11-04
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Incyte Corporation
Phase 1/2 Terminated
NCT06069778 2025-10-31
Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
BioNTech SE
Phase 1/2 Terminated
NCT04972110 2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2 Terminated
NCT05469178 2025-10-29
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
BerGenBio ASA
Phase 1/2 Terminated
NCT04035434 2025-10-24
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Phase 1/2 Terminated
NCT05220722 2025-10-23
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TriSalus Life Sciences, Inc.
Phase 1/2 Terminated
NCT03901573 2025-10-22
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
Phase 1/2 Terminated
NCT04582539 2025-10-22
LIMBER
Incyte Corporation
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT04623216 2025-10-16
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
Novartis
Phase 1/2 Terminated
NCT06563804 2025-10-14
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Phase 1/2 Terminated
NCT05326035 2025-10-02
A Study of WJ05129 in Advanced Malignant Solid Tumors
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2 Terminated